Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment for Von Willebrand Disease
December 22, 2014 at 09:00 AM EST
Baxter International Inc. (NYSE: BAX) today announced that the company has submitted a biologics license application (BLA) to the ...